Eli Lilly (NYSE:LLY) said today that it pledged up to $52 million to Purdue University as part of a 5-year research agreement. The deal is Purdue’s largest strategic collaboration with a single company, according to the university.
The group is slated to focus on improving the delivery of injectable medications with the goals of reducing pain and the frequency of injection. The researchers also plan to develop predictive models that can predict the outcomes of new therapies and lower the risks associated with investing in drug development.
Get the full story at our sister site, Drug Delivery Business News.
The post Eli Lilly pledges up to $52m to Purdue for improving injection tech appeared first on MassDevice.